{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:11:11Z","timestamp":1696399871144},"reference-count":141,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:00:00Z","timestamp":1397174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:p>Translational medicine is a roller coaster with occasional brilliant successes and a large majority of failures. Lost in Translation 1 (\u2018<jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>1\u2019), beginning in the 1950s, was a golden era built upon earlier advances in experimental physiology, biochemistry and pharmacology, with a dash of serendipity, that led to the discovery of many new drugs for serious illnesses. <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>2 saw the large\u2010scale industrialization of drug discovery using high\u2010throughput screens and assays based on affinity for the target molecule. The links between drug development and university sciences and medicine weakened, but there were still some brilliant successes. In <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>3, the coverage of translational medicine expanded from molecular biology to drug budgets, with much greater emphasis on safety and official regulation. Compared with <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>&amp;<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content> expenditure, the number of breakthrough discoveries in <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>3 was disappointing, but monoclonal antibodies for immunity and inflammation brought in a new golden era and kinase inhibitors such as imatinib were breakthroughs in cancer. The pharmaceutical industry is trying to revive the <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>1 approach by using phenotypic assays and closer links with academia. <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>4 faces a data explosion generated by the genome project, <jats:styled-content style=\"fixed-case\">GWAS<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">ENCODE<\/jats:styled-content> and the \u2018omics\u2019 that is in danger of leaving <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>4 in a computerized cloud. Industrial laboratories are filled with masses of automated machinery while the scientists sit in a separate room viewing the results on their computers. Big Data will need Big Thinking in <jats:styled-content style=\"fixed-case\">LiT<\/jats:styled-content>4 but with so many unmet medical needs and so many new opportunities being revealed there are high hopes that the roller coaster will ride high again.<\/jats:p>","DOI":"10.1111\/bph.12580","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T03:46:49Z","timestamp":1389844009000},"page":"2269-2290","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lost in Translation (<scp>LiT<\/scp>): <scp>IUPHAR<\/scp> Review 6"],"prefix":"10.1111","volume":"171","author":[{"given":"Colin T","family":"Dollery","sequence":"first","affiliation":[{"name":"R&amp;D Management GlaxoSmithKline  Stevenage Essex UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"e_1_2_42_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2047873"},{"key":"e_1_2_42_3_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1948.153.3.586"},{"key":"e_1_2_42_4_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2009.167"},{"key":"e_1_2_42_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7141.1337"},{"key":"e_1_2_42_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.04.026"},{"key":"e_1_2_42_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-007-1486-6"},{"key":"e_1_2_42_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.002"},{"key":"e_1_2_42_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.02.325"},{"key":"e_1_2_42_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_42_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.36.040196.000245"},{"key":"e_1_2_42_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"e_1_2_42_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd706"},{"key":"e_1_2_42_14_1","unstructured":"BonislawskiA(2013).The unsteady march of cancer protein biomarkers into the clinic. The Global Newsweekly of Proteomic Technology (May 10 2013)."},{"key":"e_1_2_42_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e328337282f"},{"issue":"3","key":"e_1_2_42_16_1","first-page":"233","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan FR","year":"2010","journal-title":"Landes Bioscience"},{"key":"e_1_2_42_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.08.001"},{"key":"e_1_2_42_18_1","first-page":"1","article-title":"Bispecific antibodies for cancer therapy. The light at the end of the tunnel?","volume":"1","author":"Chames P","year":"2009","journal-title":"Landes Bioscience"},{"key":"e_1_2_42_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"e_1_2_42_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0478-8"},{"key":"e_1_2_42_21_1","unstructured":"ClintonW BlairT(2000).The White House Office of the Press Secretary. Available at:http:\/\/www.genome.gov\/10001356(accessed 24\/2\/2014)."},{"key":"e_1_2_42_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012035"},{"key":"e_1_2_42_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.37"},{"key":"e_1_2_42_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6150-7-43"},{"key":"e_1_2_42_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-398339-8.00004-5"},{"key":"e_1_2_42_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15109"},{"key":"e_1_2_42_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.10.010"},{"key":"e_1_2_42_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-3-S1-S6"},{"key":"e_1_2_42_29_1","unstructured":"Department of Health(2006).Expert Group on Phase I Clinical Trials Final Report (Chaired by Professor Sir Gordon W. Duff). Available at:http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_063117(accessed 24\/2\/2014)."},{"key":"e_1_2_42_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1625"},{"key":"e_1_2_42_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.240"},{"key":"e_1_2_42_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2010.12.013"},{"key":"e_1_2_42_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0027-4"},{"key":"e_1_2_42_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.2.247"},{"key":"e_1_2_42_35_1","first-page":"831","article-title":"Problems of communication of a drug regulatory authority","volume":"70","author":"Dunlop D","year":"1977","journal-title":"Proc R Soc Med"},{"key":"e_1_2_42_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_42_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00922.x"},{"key":"e_1_2_42_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/489052a"},{"key":"e_1_2_42_39_1","doi-asserted-by":"publisher","DOI":"10.1006\/immu.1993.1054"},{"key":"e_1_2_42_40_1","doi-asserted-by":"publisher","DOI":"10.1039\/c2mb25063b"},{"key":"e_1_2_42_41_1","unstructured":"Food and Drug Administration(2012).FDA Guidance for Industry Drug Interaction Studies Study Design Data Analysis Implications for Dosing and Labelling Recommendations. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf(accessed 24\/2\/2014)."},{"key":"e_1_2_42_42_1","unstructured":"Food and Drug Administration(2013).Approved Risk Evaluation and Mitigation Strategies (REMS). Available at:http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm111350.htm(accessed 24\/2\/2014)."},{"key":"e_1_2_42_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1090051"},{"key":"e_1_2_42_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01516-12"},{"key":"e_1_2_42_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-2586(199911)10:5<602::AID-JMRI3>3.0.CO;2-C"},{"key":"e_1_2_42_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/489208b"},{"key":"e_1_2_42_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/gbe\/evt028"},{"key":"e_1_2_42_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1704-y"},{"key":"e_1_2_42_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2220"},{"key":"e_1_2_42_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2918"},{"key":"e_1_2_42_51_1","unstructured":"Harvard Medical School(2011).Initiative in Systems Pharmacology. Available at:http:\/\/isp.hms.harvard.edu\/(accessed 24\/2\/2014)."},{"key":"e_1_2_42_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002529"},{"key":"e_1_2_42_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.4.749"},{"key":"e_1_2_42_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.198908791"},{"key":"e_1_2_42_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0754"},{"key":"e_1_2_42_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2003.08.007"},{"key":"e_1_2_42_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043186"},{"key":"e_1_2_42_58_1","unstructured":"Human Metabolome Database.Strengthening\u2010big\u2010data\u2010in\u2010the\u2010pharmaceutical\u2010industry. Available at:http:\/\/www.hmdb.ca\/(accessed 25\/2\/2014)."},{"key":"e_1_2_42_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2009.01.028"},{"key":"e_1_2_42_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020124"},{"key":"e_1_2_42_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2013.768864"},{"key":"e_1_2_42_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.2"},{"key":"e_1_2_42_63_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006213"},{"key":"e_1_2_42_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1090-x"},{"key":"e_1_2_42_65_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094715"},{"key":"e_1_2_42_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3166"},{"key":"e_1_2_42_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60104-X"},{"key":"e_1_2_42_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq030"},{"key":"e_1_2_42_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/35051706"},{"key":"e_1_2_42_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_2_42_71_1","first-page":"182","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann RE","year":"2012","journal-title":"Landes Bioscience"},{"key":"e_1_2_42_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/RTI.0b013e31827882d9"},{"key":"e_1_2_42_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.06.002"},{"key":"e_1_2_42_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2445"},{"key":"e_1_2_42_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.06.006"},{"key":"e_1_2_42_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380303"},{"key":"e_1_2_42_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-007-0772-1"},{"key":"e_1_2_42_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0608107"},{"key":"e_1_2_42_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2004.11.007"},{"key":"e_1_2_42_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/368856a0"},{"key":"e_1_2_42_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/489046a"},{"key":"e_1_2_42_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks794"},{"key":"e_1_2_42_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12508"},{"key":"e_1_2_42_84_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1075762"},{"key":"e_1_2_42_85_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233606"},{"key":"e_1_2_42_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/498255a"},{"key":"e_1_2_42_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04085.x"},{"key":"e_1_2_42_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/348552a0"},{"key":"e_1_2_42_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12564"},{"key":"e_1_2_42_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6488.97"},{"key":"e_1_2_42_91_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"e_1_2_42_92_1","doi-asserted-by":"publisher","DOI":"10.3945\/an.111.000554"},{"key":"e_1_2_42_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353995"},{"key":"e_1_2_42_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.12.020"},{"key":"e_1_2_42_95_1","volume-title":"The Emperor of All Maladies: A Biography of Cancer","author":"Mukherjee S","year":"2011"},{"key":"e_1_2_42_96_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787002933"},{"key":"e_1_2_42_97_1","unstructured":"National Cancer Institute(2013).Office of Cancer Clinical Proteomics Research\/CPTAC Data Portal Overview (2011\u2013present). Available at:http:\/\/proteomics.cancer.gov(accessed 3\/2014)."},{"key":"e_1_2_42_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/437169b"},{"key":"e_1_2_42_99_1","unstructured":"Nature\/omics(2010).Home page. Available at:http:\/\/www.nature.com\/omics\/index.html(accessed 24\/2\/2014)."},{"key":"e_1_2_42_100_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2006.tb00662.x"},{"key":"e_1_2_42_101_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0720263"},{"key":"e_1_2_42_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-8-21"},{"key":"e_1_2_42_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.002"},{"key":"e_1_2_42_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.071"},{"key":"e_1_2_42_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(80)90066-3"},{"key":"e_1_2_42_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3314"},{"key":"e_1_2_42_107_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.15.1453"},{"key":"e_1_2_42_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3439-c1"},{"key":"e_1_2_42_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404357"},{"key":"e_1_2_42_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1235"},{"key":"e_1_2_42_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.54"},{"key":"e_1_2_42_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007768.pub2"},{"key":"e_1_2_42_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_42_114_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799436368"},{"key":"e_1_2_42_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2011.07.004"},{"key":"e_1_2_42_116_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524053152825"},{"key":"e_1_2_42_117_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac0483062"},{"key":"e_1_2_42_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2017"},{"key":"e_1_2_42_119_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920005774832632"},{"key":"e_1_2_42_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.277"},{"key":"e_1_2_42_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07762"},{"key":"e_1_2_42_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"e_1_2_42_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1211"},{"key":"e_1_2_42_124_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9182-4"},{"key":"e_1_2_42_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-005-8694-y"},{"key":"e_1_2_42_126_1","unstructured":"The Wellcome Trust(2009).Coming up trumps: Genome\u2010wide association studies. Available at:http:\/\/www.wellcome.ac.uk\/about\u2010us\/publications\/annual\u2010review\/wtdv027330.htm(accessed 24\/2\/2014)."},{"key":"e_1_2_42_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1112"},{"key":"e_1_2_42_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_2_42_129_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.816116"},{"key":"e_1_2_42_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430080103"},{"issue":"12","key":"e_1_2_42_131_1","first-page":"IV12","article-title":"History of aspirin and its mechanism of action","volume":"21","author":"Vane JR","year":"1990","journal-title":"Stroke; a Journal of Cerebral Circulation"},{"key":"e_1_2_42_132_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.007"},{"key":"e_1_2_42_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2484"},{"key":"e_1_2_42_134_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920011795202947"},{"key":"e_1_2_42_135_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105903"},{"key":"e_1_2_42_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05058"},{"key":"e_1_2_42_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.09.028"},{"key":"e_1_2_42_138_1","first-page":"3","article-title":"Can animal models of disease reliably inform human studies?","volume":"7","author":"Worp HB","year":"2010","journal-title":"PLoS Med"},{"key":"e_1_2_42_139_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5958.595"},{"key":"e_1_2_42_140_1","unstructured":"Wyss(2013).Wyss Institute for Biologically Inspired Engineering. Available at:http:\/\/integralife.com\/(accessed 25\/2\/2014)."},{"key":"e_1_2_42_141_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M019927"},{"key":"e_1_2_42_142_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb053723"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbph.12580","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.12580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:11:58Z","timestamp":1696299118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.12580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":141,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/bph.12580"],"URL":"https:\/\/doi.org\/10.1111\/bph.12580","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]},"assertion":[{"value":"2013-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}